be presented to target cells in the form of soluble peptide hormones, proteins retained on the surface of adjacent cells, or as part of the extracellular matrix (ECM). Manygrowth factors activate membrane-associated receptor protein-tyrosine kinases (PTKs), which in turn stimulate intracellular signal transduction pathways.
Whereas muchprogress has been madein characterizing growth factor receptor PTKs signal transduction, less is known about the mechanisms by which signals from the extracellular matrix are transduced into the interior of the cell. Extracellular matrix proteins such as fibronectin, vitronectin, laminin, and collagen bind to a family of heterodimeric transmembrane proteins called integrins. The integrin receptors cluster at distinct sites of cell contact with the ECMtermed focal adhesions, and one of their roles is to link the interior actin cytoskeleton of cells with ECMproteins. This structural linkage of the actin cytoskeleton with integrins is believed to be mediated by cytoskeletal-associated proteins such as talin and a-actinin which can bind to integrin cytoplasmic domains (for a review see 1) . In addition to a structural role, integrin receptor binding to ECMresults in the activation of a numbersignal transduction pathwayssimilar to those of stimulated by growth factors and cytokines (for a reviews see 2, 3, 4, 5, 6, 7) . Integrin induced signals include calcium influx (8, 9) , proton exchange (10), changes in phosphoinositide metabolism (ll, 12, 13, 14, 15) , stimulation of enhanced protein-tyrosine phosphorylation (16, 17, 18) , and can lead to the activation of mitogen-activated protein (MAP)-ERK (19, 20, 21, 22 ) and c-jun N-terminal (JNK) MAPkinase cascades (23). Integrin-induced cellular responses in the nucleus can stimulate specific gene expression (24, 25, 26, 27, 28) , prevent apoptotic cell death (29, 30, 31, 32) , and can promote DNAsynthesis and cell growth (33, 34, 35) .
Integrins are composed of a and /3 type transmembrane subunits, amongwhich 16a and 8/3 subunits can heterodimerize to form more than 20 different integrin receptors (1) . The relatively short cytoplasmic domains of the a and /3 integrin subunits do not have any intrinsic enzymatic activity and likely transduce intracellular signals by promoting the formation of multi-protein complexes containing both cytoskeletal and catalytic signaling proteins (23, 36) . Protein phosphorylation is one of the earliest events detected in response to integrin stimulation. Someof the first evidence that integrin receptors could induce protein-tyrosine phosphorylation came from studies in platelets (for reviews see 6, 37) . Tyrosine phosphorylation of 50-72 kDa platelet proteins occur on immobilized fibrinogen (38, 39) , whereas subsequent increased tyrosine phosphorylation of other proteins (120-140 kDa) require platelet-platelet aggregation or cell spreading (40, 41) . Subsequent studies have specifically identified the protein-tyrosine kinase, Syk, as being rapidly activated in response to fibrinogen binding to the integrin receptor, allbft, in platelets (42). Increased tyrosine phosphorylation has been shown to be a commonresponse to integrin engagement in manycell types including fibroblasts, carcinoma cells, and cells of hematopoietic lineages (for a review see 7).
In fibroblasts, several protein-tyrosine kinases have been implicated in integrin signaling events by virtue of their integrin-dependent activation or their localization to focal contacts. Members of the Src-family of protein-tyrosine kinases have been implicated in integrin signaling events due to the fact that v-Src or constitutively activated forms of c-Src localize to focal contacts (43, 44) . In addition, in cells which are deficient in the Csk protein-tyrosine kinase which phosphorylates and negatively regulates c-Src, c-Src is activated and localized to focal adhesions (45, 46, 47, 48) .
Another protein-tyrosine kinase that appears to play a central role in integrin-mediated signal transduction is the cytoplasmic focal adhesion protein-tyrosine kinase (FAK). In fibroblasts, FAKnormally localizes with surface integrin receptors at sites wherecells attach to the ECM(49, 50), and is activated by cell binding to fibronectin (16, 18, 21, 49, 50) or by extracellular antibody cross-linking of /31 integrins (16, 51) . In vitro, FAK has been shownto interact with short peptides from several /3 integrin cytoplasmic domains (52) and can bind to the cytoskeletal protein talin, which also can associate with / 3 integrin cytoplasmic domains (53). Since the transmembraneintegrin receptors lack endogenous catalytic activity and need to recruit signaling molecules, recent research interest has been focused on FAKas a likely candidate for a key signaling molecule which is recruited and activated by integrin receptors in order to promote intracellular signal transduction.
Mechanisms of Integrin-mediated Signaling/A Role for the FAK PTK Family FAK was originally identified as the 125 kDa target of a monoclonal antibody produced against a panel of v-Src associated tyrosine phosphorylated proteins (54). Subsequently, the FAK CDNAwas cloned both by using this monoclonal antibody to screen a chicken expression library (50) and independently cloned from a mouse CDNAlibrary using degenerate PCRprimers to conserved motifs found in PTKcatalytic domains (49). FAKhomologues also have been cloned from human (55, 56) and Xenopus CDNAlibraries (57, 58) and the predicted protein sequences from human, mouse, chicken, and Xenopus FAKshare over 90%identities. FAK is ubiquitously expressed in many tissues, found in focal adhesions as its nameimplies, and is unusual among non-receptor protein-tyrosine kinases in that it does not contain Src-homology 2 (SH2) or SH3 domains. FAKis comprised of a central kinase domain flanked by two large non-catalytic domains. The FAKC-terminal domain contains sequences required for focal adhesion localization (59), as well as binding sites for other cellular proteins. The cytoskeletal protein, paxillin, binds to residues in the tail of the FAKC-terminal domain (60) and has been shown to be phosphorylated by FAKin vitro (61). Conserved tyrosines residues in the FAKC-terminal domain have been shown be phosphorylated in vivo (62) and in particular, FAKTyr925 (YENVmotif) serves as a binding site for the SH2 domain of the GRB2SH2/SH3 adaptor protein (21 , 63). The FAKC-terminal domain also contains conserved proline-rich motifs. It has been shown that the SH3 domain of pl30Cas (64), the major phosphoprotein associated with the v-Crk oncoprotein (65), bound to a proline-rich motif (residues 711-717) in FAK. The kinetics of increased pl30Cas phosphorylation on tyrosine after integrin stimulation by fibronectin in intact cells (66, 67, 68) are very similar to that of FAKwith the implication being that pl30Cas may be a physiological substrate of FAK. In addition, the SH3domain of the p85 subunit of PI3-kinase has been shown to bind FAK in vitro (13). PI3 kinase activity associated with FAK immunoprecipites is enhanced after fibronectin and growth factor stimulation of cells (12, 69). Specific cellular protein binding the FAKN-terminal non-catalytic domain also has been demonstrated in vitro and in vivo. FAK Tyr397 (YAEI motif) is one of the major FAKautophosphorylation sites (62, 70), and also serves as a binding site for the SH2 domain of Srcfamily protein-tyrosine kinases (70, 71, 72) . Mutation of FAKTyr397 to Phe disrupts Src binding to FAKin vivo (70), results in a significant reduction of FAKphosphotyrosine content (70), but only results in a modest decrease in the ability of FAKto transphosphorylate exogenous substrates (62). Mutation of autophosphorylated tyrosine residues (Tyr576 and Tyr577) in the kinase domainactivation loop or mutation of a conserved lysine residue in the predicted ATP-binding loop of the FAKcatalytic domain (Lys454) results in a loss of FAK kinase activity (62). The autophosphorylation of FAK at Tyr397 outside of the catalytic domain may be due to either inter or intra-molecular FAKphosphorylation events. Evidence for intra-molecular FAKphosphorylation of Tyr397 was obtained using recombinant FAK chimeras that were transmembrane-anchored with the addition of CD2 extracellular sequences (73). These FAK chimeras exhibited enhanced kinase activity in vitro and tyrosine phosphorylation in vivo with CD2 antibody-mediated clustering of the recombinant FAK constructs.
The significance of FAK Tyr397 phosphorylation may be a means by which FAKcan recruit Src-family tyrosine kinases to focal adhesion structures. In Srctransformed cells, a stable association between activated Src and FAK can be detected (71). We have shown that integrin stimulation by replating cells on fibronectin promotes the transient association of c-Src and FAKin vivo in non-transformed mouse NIH3T3 fibroblasts (21). Interestingly, the Src SH2 domain can also bind strongly to FAKTyr397 in vitro in serum starved fibroblasts where no in vivo co-immunoprecipitation of FAKand c-Src can be detected. These results indicate that FAKand c-Src may be independently regulated and that their association in vivo maybe mediated by other factors such as the dephosphorylation of the negative-regulatory tyrosine in the c-Src C-terminal domain (for a review see 74) or by allosteric activation of FAKmolecules that lead to the exposure of the phosphorylated Tyr397 residue as a high-affinity Src SH2 binding site. As we will discuss below, this formation of a FAK/Src bipartite kinase complex is intimately involved in the processes of integrin-mediated signal transduction. /CAK/3 is slightly smaller than FAK (112 kDa) and is highly expressed in tissues of the central nervous system. PYK2/CAK/3 autophosphorylates on tyrosine in vitro and when over-expressed in COS-7 cells, it is found localized in junctions of cell to cell contact but not in focal adhesions (76). PYK2/CAK/3 may not be regulated by cell adhesion to fibronectin (76), but instead it may be activated by calcium-mediated signaling events (75). Various stimuli that increase intracellular calcium levels, such as carbachol, calcium ionophores, and bradykinin, result in increased levels of PYK2 /CAK/3 tyrosine phosphorylation in vivo and increased PYK2/CAK/3 in vitro kinase activity (75). Comparisons between FAKand PYK2/CAK/3 also reveal that they both contain conserved tyrosine residues and sequence motifs for SH2 binding sites in similar regions of the two proteins. The Src SH2 binding site on FAK Tyr397 (YAEI motif) has been completely conserved in PYK2/CAK/3 at Tyr402 (YAEI). In addition, the GRB2 SH2 binding site on FAK Tyr925 (YENV) has been conserved at an analogous site on PYK2 /CAK/3 Tyr881 (YHNV). Although Tyr881 of PYK2 /CAK/3 has not yet been proven to be the GRB2SH2 binding site, GRB2has been shown to bind directly to phosphorylated PYK2/CAK/3immobilized on a membrane (75). The potential conservation of both the Src and GRB2 SH2 binding sites on FAK and PYK2/CAK/3 reinforce the hypothesis that these tyrosine kinases are central regulators of similar signal transduction pathways.
PYK2/CAK£ -New Member of the FAK Family
GRB2 Binding to FAK and PYK2/CAK£-Linkage to Ras-MAPKActivation In general, transmembrane receptor PTKautophosphorylation can create specific high affinity binding sites for the Src homology 2 (SH2) domains of cytoplasmic proteins and lead to the formation of multimeric signaling complexes (for reviews see 77, 78). For example, the binding of the modular adaptor protein, GRB2, couples receptor PTKsto the Ras guanine nucleotide exchange factor, SOS, which in turn is able to activate Ras by converting it from the inactive GDP-boundstate to the active GTP-bound form (79). GRB2 binds to specific phosphotyrosine sites on activated receptor PTKs through its SH2 domain, and to proline-rich motifs in Sos through its SH3 domains, thereby serving as a linker on "adaptor" between the two enzymes.
Our research has been focused on elucidating the molecular mechanisms involved in fibronectin-mediated signal transduction involving GRB2as outlined in the model below (Fig. 1) .
We have found that fibronectin stimulation of NIH3T3mouse fibroblasts leads to the transient association of a FAK/c-Src bipartite signaling complex. Both increased FAKand c-Src in vitro kinase activities have been detected after fibronectin stimulation (18, 21, 80) . the transient association of GRB2with FAKhas been detected. GRB2binds to FAKdirectly through its SH2 domain and mutation of FAKTry925 (YENVmotif) abolishes fibronectin-mediated GRB2binding in vitro and in vivo (Schlaepfer and Hunter, submitted) . Mutation of the c-Src binding site on FAK(Tyr397) also disrupts GRB2binding to FAKin vivo after fibronectin stimulation (Schlaepfer and Hunter, submitted) . The conclusion from this result is that c-Src kinase association and activity is necessary for the tyrosine phosphorylation of FAKTyr925. Fibronectin stimulation of NIH3T3cells also activates the ERK-2 MAPkinase with a time course similar to those of c-Src and GRB2association with FAK. Activation of the ERK/MAPkinase pathway possibly occurs through the induction of integrin-aggregated multiprotein complexes (23). Fibronectin stimulation has been shownalso to promotethe nuclear translocation of MAPK(19) . Similarly, over-expression of PYK2 /CAK/3 in human embryonic kidney 293 cells has been shown to increase ERK-2/MAPK activity in a PYK2 /CAK/3 concentration-dependent manner (75). Fibronectin-stimulated ERK-2/MAPKactivation is gradual and sustained over a period of approximately sixty minutes and has been correlated with cell spreading (19, 22) . We have found that fibronectin-stimulated MAPK activation is inhibited by the tyrosine kinase inhibitors genistein, herbimycin A, tyrphostin AG213 as well as cytochalasin D which disrupts the integrity of the actin cytoskeleton (Schlaepfer and Hunter, submitted) . Both the fibronectin-stimulated increase in FAKand c-Src in vitro kinase activities are reduced in cells treated with cytochalasin D or with the tyrosine kinase inhibitors. Other drug treatments such as wortmannin, which inhibits PI-3 kinase activity, and protein kinase C inhibitors, calphostin C and chronic TPAtreatment which downregulates PKC, did not affect fibronectin-stimulated ERK-2/MAPKactivation. These results suggest that increased tyrosine kinase activity is necessary and sufficient for fibronectin-stimulated signal transduction to MAPK. In order to determine the role that c-Src plays in fibro- FAKdeficiencies, mutant embryos displayed a general defect of mesodermal development. A number of interesting conclusions can been madefrom these knock-out results. Primarily, the fact the both the fibronectin and FAKdeficiencies yielded strikingly similar phenotypes, indicates that fibronectin signaling through FAKactivation is critical in development. Surprisingly, FAK-deficient cells were isolated from mutant embryosand these cells exhibited enhanced focal adhesion contact formation and reduced rates of cell motility and migration when stimulated by fibronectin (83).
These results suggest that FAK-mediated processes may be involved in the turnover of focal adhesion contacts during cell migration. In support of the role for FAKactivation with the processes of cell motility, recent medical studies have correlated increased levels of FAK expression with human tumors exhibiting enhanced metastatic and invasive properties (84, 85) . It is interesting to speculate on the role of FAK-mediatedsignal transduction to ERK-2/MAPKwith respect to cell migration events. Manygrowth factors and mitogens that can stimulate cell migration also enhance the level of FAKtyrosine phosphorylation (86). In tissue wounding and cell migration assays, the increased level of FAKtyrosine phosphorylation has been correlated with migrating cells (87, 88). In Xenopus developmental systems, dominant-negative ERK-2/MAPK constructs have been shown to interfere with proper FGF/activininduced mesoderm development (89). In mammalian cells, micro-injected antibodies to Ras have been shown to inhibit endothelial cell migration events (90). Clearly, future research endeavors will be aimed at elucidating a more precise role of the FAK-GRB2-Ras-ERK-2 /MAPKsignal transduction pathway in mediating cell migration processes.
